April 21, 2010, St. Louis Post Dispatch
From St. Louis Post Dispatch:
Another local startup, C2N Diagnostics, is working with pharmaceutical companies to develop a test that can detect Alzheimer's at its earliest stages and also to guide effective treatment before patients manifest clinical symptoms. By the time symptoms are observed, neurological damage has occurred. So the goal is to catch Alzheimer's early — to delay or prevent symptoms in someone who has a high risk of developing it in the future.
"We need better measurements and tools to both discover drugs for Alzheimer's as well as to develop them clinically," said Joel Braunstein, a co-founder of C2N.
Cutting health care costs is just one of the messages pitched by medical entrepreneurs to investors.